Sera Prognostics Stock (NASDAQ:SERA)
Previous Close
$7.30
52W Range
$1.56 - $12.36
50D Avg
$7.22
200D Avg
$7.65
Market Cap
$248.19M
Avg Vol (3M)
$187.57K
Beta
1.03
Div Yield
-
SERA Company Profile
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.